Expert opinion on translational research for advanced glioblastoma treatment

作     者：Xiaoteng Cui Yunfei Wang Junhu Zhou Qixue Wang Chunsheng Kang Xiaoteng Cui;Yunfei Wang;Junhu Zhou;Qixue Wang;Chunsheng Kang

作者机构：Laboratory of Neuro-oncologyTianjin Neurological InstituteKey Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous SystemMinistry of Education and Tianjin CityTianjin Medical University General HospitalTianjin 300052China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2023年第20卷第5期

页      面：344-352页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Natural Science Foundation of China(Grant Nos.82272893 and 82002657) from Tianjin Key R&D Plan of Tianjin Science and Technology Plan Project(Grant No.20YFZCSY00360)。 

主　　题：Malignant gliomas glioblastoma temozolomide chemoresistance small molecule drugs 

摘      要：Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern,rapid progression,and poor prognosis.Many antitumor drugs are not ideal for the treatment of gliomas due to the blood-brain barrier.Temozolomide(TMZ)is a DNA alkylating agent that can cross the blood-brain barrier.As the only first-line chemotherapeutic drug for malignant gliomas at present,TMZ is widely utilized to provide a survival benefit;however,some patients are inherently insensitive to TMZ.In addition,patients could develop acquired resistance during TMZ treatment,which limits antitumor efficacy.To clarify the mechanism underlying TMZ resistance,numerous studies have provided multilevel solutions,such as improving the effective concentration of TMZ in tumors and developing novel small molecule drugs.This review discusses the in-depth mechanisms underlying TMZ drug resistance,thus aiming to provide possibilities for the establishment of personalized therapeutic strategies against malignant gliomas and the accelerated development and transformation of new targeted drugs.